Regeneron Pharmaceuticals Inc
Company Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with San...
Analysis Summary
Eylea franchise stable despite biosimilar concerns. Dupixent growth accelerating. Obesity and oncology pipelines underappreciated.
Pro Analysis Locked
Upgrade to Pro to unlock detailed financial analysis, historical data, comparable companies, and AI-generated research reports.